Vaccine researchers have developed a strategy aimed at generating broadly cross-reactive antibodies against the influenza virus: embrace the unfamiliar.
(HealthDay)—An experimental drug shows promise in treating respiratory syncytial virus (RSV), a leading cause of pneumonia in infants, researchers report.
It is well known that chronic drinking is associated with an increased incidence and severity of respiratory infections. Previous research had demonstrated that an increase in disease severity to influenza virus (IAV) infections ...
Japan said Monday it is ready to provide a Japanese-developed anti-influenza drug as a possible treatment for the rapidly expanding Ebola outbreak.